Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 64 citations · 22 references
MedicineOncologyPathologyMolecular VirologySurgical OncologyThoracic OncologyKaposi SarcomaMalignant NeoplasmsOncogenic VirusesHuman Herpesvirus 8Malignant Pleural EffusionPericardial Involvement In MalignancyPrimary Effusion LymphomaPrognostic Factors Analysis
Primary effusion lymphoma (PEL) is a rare lymphoma associated with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), and characterized by a malignant body cavity effusion without solid organ or nodal involvement. Prognostic factors in patients with PEL have not been systematically studied. We conducted a literature search for patients with HHV8-positive PEL to identify potential prognostic factors for survival. Our search identified 147 patients, among which 104 patients were HHV8-positive. The median overall survival was 9 months. The median age was 57 years with a male predominance (6:1). Pathologically, 33% of the patients expressed CD20 and 69% expressed CD30. Patients with PEL with > 1 body cavity involved had a median overall survival (OS) of 4 months compared with 18 months in patients with only one cavity involved (p = 0.003). Additionally, in patients with one involved body cavity, pericardial involvement was associated with a longer median OS than pleural followed by peritoneal involvement (40, 27 and 5 months, respectively; p = 0.04). In conclusion, our study suggests that the number and location of body cavities involved are prognostic in patients with PEL.
22
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
p53 inhibition by the LANA protein of KSHV protects against cell death
Jacques Friborg, Wing‐Pui Kong, Michael O. Hottiger et al. · Nature · 1999 · 709 citations